Zydus announces Phase I trials of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor

Zydus, a leading discovery based, global pharmaceutical company today announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.

NLRP3 inflammasomes are involved in the inflammation process by production and release of proinflammatory cytokines IL-1β and IL-18. This harmful inflammation within the body leads to the onset and development of various kinds of diseases, including Acute Respiratory Distress Syndrome (ARDS), auto-immune diseases, inflammatory diseases, cardiovascular diseases, metabolic disorders, Gastro-intestinal diseases (inflammatory bowel disease), renal diseases and CNS diseases.

Speaking on the development, Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said, "We will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in this Phase I clinical trial in healthy human volunteers. We are committed to developing these pioneering novel treatments to the clinic for the patients in need."

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.471 as compared to the previous close of Rs. 462.8. The total number of shares traded during the day was 255211 in over 5266 trades.

The stock hit an intraday high of Rs. 475.85 and intraday low of 457.95. The net turnover during the day was Rs. 119545015.

Source : Equity Bulls

Keywords